Offentliggjort den 5. jun. 2016
Antonio Palumbo, Asher Alban Akmal Chanan-Khan, Katja Weisel, et alt. Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. Abstract LBA4.
Antonio Palumbo, Asher Alban Akmal Chanan-Khan, Katja Weisel, et alt. Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. Abstract LBA4.
5/6 2016 17:31 Helge Larsen/PI-redaktør 2
74795 Genmab - Offentliggjort den 5. jun. 2016
Dr. Sagar Lonial from the Winship Cancer Institute, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO) meeting in Chicago, IL.
Dr. Sagar Lonial from the Winship Cancer Institute, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO) meeting in Chicago, IL.
5/6 2016 17:34 Helge Larsen/PI-redaktør 374796 Genmab - Mere fra Antonio Palumbo.
Offentliggjort den 5. jun. 2016
Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Offentliggjort den 5. jun. 2016
Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
5/6 2016 17:45 Helge Larsen/PI-redaktør 274797 Genmab - ASCO 2016 - Diverse links.
http://abstracts.asco.org/176/AbstView_176_172609.html
https://www.asco.org/about-asco/press-center/news-releases/novel-daratumumab-based-regimen-slows-multiple-myeloma?sthash.NIsLYkV2.mjjo
http://www.channelnewsasia.com/news/health/j-j-myeloma-drug-in-comb/2847220.html
http://www.ft.com/cms/s/0/37be4b2e-29d9-11e6-8ba3-cdd781d02d89.html?siteedition=uk#axzz4Aj6xj6kj
http://abstracts.asco.org/176/AbstView_176_172609.html
https://www.asco.org/about-asco/press-center/news-releases/novel-daratumumab-based-regimen-slows-multiple-myeloma?sthash.NIsLYkV2.mjjo
http://www.channelnewsasia.com/news/health/j-j-myeloma-drug-in-comb/2847220.html
http://www.ft.com/cms/s/0/37be4b2e-29d9-11e6-8ba3-cdd781d02d89.html?siteedition=uk#axzz4Aj6xj6kj
5/6 2016 18:51 Helge Larsen/PI-redaktør 274799 Genmabs vidundermiddel leverer historisk gode data.
http://finans.dk/protected/finans/erhverv/ECE8734436/genmabs-vidundermiddel-leverer-historisk-gode-data/?ctxref=fplive
http://finans.dk/protected/finans/erhverv/ECE8734436/genmabs-vidundermiddel-leverer-historisk-gode-data/?ctxref=fplive
5/6 2016 22:45 Helge Larsen/PI-redaktør 174803 Dagens Medicin i Norge:
http://www.dagensmedisin.no/artikler/2016/06/05/benmargskreft-studie--redusert-risiko-for-progresjon-med-daratumumab/
http://www.dagensmedisin.no/artikler/2016/06/05/benmargskreft-studie--redusert-risiko-for-progresjon-med-daratumumab/
6/6 2016 16:09 Helge Larsen/PI-redaktør 274807 Castorvideo.
Offentliggjort den 6. jun. 2016
Antonio Palumbo, MD, discusses the "unprecedented" results of the CASTOR Trial, a plenary, late-breaking abstract at ASCO 2016.
Offentliggjort den 6. jun. 2016
Antonio Palumbo, MD, discusses the "unprecedented" results of the CASTOR Trial, a plenary, late-breaking abstract at ASCO 2016.
